ArticleExperimental hematology & oncology2025

Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors.

Rongrui Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.